Literature DB >> 20351189

Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death.

Benyue Zhang1, Yuanyuan Zhang, Liguo Niu, Anthony T Vella, Robert S Mittler.   

Abstract

Agonistic anti-CD137 mAbs either positively or negatively regulate T cell function. When administered at the beginning of lymphocytic choriomeningitis virus Armstrong infection anti-CD137 induced immunosuppression and T cell deletion, and in the case of influenza infection led to increased mortality. In contrast, 72 h delay in anti-CD137 treatment led to an enhanced virus-specific CD8 T cell response and rapid viral clearance. Virus-specific CD8 T cells in anti-CD137-injected mice rapidly upregulate Fas expression, and although necessary, was insufficient to induce CD8 T cell deletion. Strikingly, CD137 signaling in T cells was found to be insufficient to induce suppression or deletion. Rather, immunosuppression and T cell deletion was only observed if CD137 signals were provided to T cells and dendritic cells (DCs). In vitro CD137 crosslinking in DCs led to phosphorylation of Stat3, and importantly, anti-CD137 treatment of lymphocytic choriomeningitis virus Armstrong infected Stat3 conditional knock-out mice induced neither immune suppression or T cell deletion. Taken together, these data suggest that CD137 signaling in DCs can regulate CD8 T cell survival through a Stat3 and Fas-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351189     DOI: 10.4049/jimmunol.0902713

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  New approaches to design HIV-1 T-cell vaccines.

Authors:  Hélène Perrin; Glenda Canderan; Rafick-Pierre Sékaly; Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 2.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 3.  The pharmacology of second-generation chimeric antigen receptors.

Authors:  Sjoukje J C van der Stegen; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Rev Drug Discov       Date:  2015-07       Impact factor: 84.694

Review 4.  4-1BB signaling beyond T cells.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Mol Immunol       Date:  2011-01-10       Impact factor: 11.530

5.  Lipocalin 2 deficiency dysregulates iron homeostasis and exacerbates endotoxin-induced sepsis.

Authors:  Gayathri Srinivasan; Jesse D Aitken; Benyue Zhang; Frederic A Carvalho; Benoit Chassaing; Rangaiah Shashidharamurthy; Niels Borregaard; Dean P Jones; Andrew T Gewirtz; Matam Vijay-Kumar
Journal:  J Immunol       Date:  2012-07-11       Impact factor: 5.422

Review 6.  Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease.

Authors:  Byungsuk Kwon
Journal:  Exp Mol Med       Date:  2010-10-31       Impact factor: 8.718

Review 7.  Strategies to Address Chimeric Antigen Receptor Tonic Signaling.

Authors:  Adam Ajina; John Maher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.261

8.  Anti-CD137 mAb Deletes Both Donor CD4 and CD8 T Cells in Acute Graft-versus-host Disease.

Authors:  Juyang Kim; Hong Rae Cho; Byungsuk Kwon
Journal:  Immune Netw       Date:  2011-12-31       Impact factor: 6.303

9.  CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.

Authors:  W M Zinzow-Kramer; A B Long; B A Youngblood; K M Rosenthal; R Butler; A-U-R Mohammed; I Skountzou; R Ahmed; B D Evavold; J M Boss
Journal:  Genes Immun       Date:  2012-01-05       Impact factor: 2.676

10.  Up-regulation of tumor necrosis factor superfamily genes in early phases of photoreceptor degeneration.

Authors:  Sem Genini; William A Beltran; Gustavo D Aguirre
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.